-
The procurement of six major medical consumables is coming, and a large wave of consumables will usher in price reductions
Time of Update: 2022-10-31
According to the announcement, the estimated procurement quantity of this volume procurement project is estimated according to 70% of the estimated total procurement of public medical institutions in Taiyuan, Jinzhong, Xinzhou and Luliang.
-
National Health Commission Issued Guidelines for the Diagnosis and Treatment of Stomatology-related Diseases (2022 Edition)
Time of Update: 2022-10-31
General Office of the National Health Commission September 30, 2022 Health Commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps: In order to further improve the standardization level of oral diagnosis and treatment, ensure medical quality and safety, and safeguard the health rights and interests of patients, our commission commissioned the formulation and revision of guidelines for the diagnosis and treatment of oral related diseases.
-
The demand for ophthalmic medical treatment continues to grow, and related companies are ushering in a favorable situation
Time of Update: 2022-10-31
In recent years, with the aging of China's population and the widespread use of electronic products, the incidence of eye diseases is continuing to increase, and the scale of the ophthalmic medical market has shown a steady growth trend.
-
New HIV Drugs! Biktarvy ® real-world data: Safe & effective in people with HIV with various comorbidities!
Time of Update: 2022-10-31
October 25, 2022 /BioValleyBIOON/ --Gilead Sciences recently announced the three-in-one compound drug Biktarvy (Chinese trade name: Bitovir, generic name: Biktigravir tablets, bictegravir ® 50mg/emtricitabine 200mg/tenofovir propofovir 25mg, BIC/FTC/ TAF) Real World Data (RWD) from the BICSTaR study: Confirm that Biktarvy is a universally well-tolerated and effective treatment regimen, regardless of prior treatment or comorbidity status in HIV-infected patients.
-
1.5 billion cefixime drugs have welcomed 3 more pharmaceutical companies to pass the evaluation
Time of Update: 2022-10-31
Among them, 19 companies have production approvals for cefixime tablets, and the currently evaluated enterprises include Jiangsu Zhengda Qingjiang Pharmaceutical, Hunan Sheng Pharmaceutical, Zhejiang Jutai Pharmaceutical and Shenzhen Lijian Pharmaceutical that has recently been evaluated, in addition, Shandong Lukang Pharmaceutical consistency evaluation supplementary application is under review, Wenling Innovative Biomedicine | Wanbangde Pharmaceutical is under review for generic 3 types of production, which is regarded as having been evaluated after approval.
-
Local innovative pharmaceutical companies are ready to innovate and constantly break the monopoly of multinational pharmaceutical companies!
Time of Update: 2022-10-31
In recent years, national policies to encourage pharmaceutical innovation, such as volume procurement and medical insurance negotiation, have gradually advanced, in this context, local innovative drugs aim at the unmet clinical demand prospects of domestic patients, increase R&D investment, accumulate innovation, focus on the research and development of more new drugs, and constantly break the monopoly of multinational pharmaceutical companies, bringing good news to patients.
-
Matrine 10%-98% Sophora sophora extract Xi'an Quercus Ping Biology welcome consultation
Time of Update: 2022-10-31
7 【Storage Method】:Sealed in a cool, dry place 【Packing】:Aluminum foil bag 1kg/bag, 25kg/barrel or according to customer requirements 【Shelf life】:24 months 【Place of shipment】:Xi'an 【Manufacturer】:Que 【Species】: Plant extract - Sophora sophora Matrine 10%-98% Sophora Extract Xi'an Quercus Biology Welcome to consult 【Product Name】:Sophora Flavescens Extract 【English Name】:Sophora Flavescens Extract [Active Ingredients]: Matrine [Other Ingredients]: Oxidized Matrine Sophora Total Sophora [Ingredient English]: Matrine 【Molecular Formula】:C15H24N2O 【Molecular Weight】:248.
-
New drug for Huntington's disease! Austedo (deuterated butbenazine) 3 years of long-term treatment data: effective, safe and well tolerated!
Time of Update: 2022-10-31
This is an approximately 3-year open-label, single-arm, 2-cohort, multicenter extension study that is evaluating the safety and tolerability of Austedo (Chinese trade name: Antetan, generic name: deutetrabenazine, deuterium butenazine tablets) in the long-term treatment of Huntington's disease (HD)-related chorea.
-
Market analysis of water-soluble jujube extract Jujube polysaccharide 30%
Time of Update: 2022-10-31
Market analysis of water-soluble jujube extract Jujube polysaccharide 30% 1. Market analysis of water-soluble jujube extract Jujube polysaccharide 30% Product introduction 【Product Name】:Jujube extra
-
The road to the rise of China's innovative drugs: too much Lilly, too few Novo Nordisks
Time of Update: 2022-10-31
/ 03 / China's innovative pharmaceutical companies also need more ingenuity Lilly's model is worth learning, and Novo Nordisk's model can also be learned.
/ 03 / China's innovative pharmaceutical companies also need more ingenuity Lilly's model is worth learning, and Novo Nordisk's model can also be learned.
-
The net profit of pharmaceutical stocks soared from 50 million to 16 billion, and only 3 companies lost money
Time of Update: 2022-10-25
Jiuan Medical soared 300 times to become the "growth king", the net profit soared from 50 million yuan to 16 billion yuan, the CXO leading performance soared, and chain giants such as Laobai, Da Shenlin and Yifeng steadily climbed.
-
$610 million! Leading multinational pharmaceutical manufacturers launched large acquisitions
Time of Update: 2022-10-25
Currently, Akoouos is developing viral gene therapy for the treatment of inner ear disorders, including sensorineural hearing loss.
Currently, Akoouos is developing viral gene therapy for the treatment of inner ear disorders, including sensorineural hearing loss.
-
Mindray, WuXi and Hengrui set off a "buyback wave"! Multi-dimensional "bottoming" boost
Time of Update: 2022-10-25
According to incomplete statistics from the New Media Center of "Medical Economic News", in the past month, WuXi Biologics has been active in repurchases, with a total of nearly 1 billion Hong Kong dollars invested in eight repurchase executions and more than 20 million shares repurchased (data as of the close of the market on October 14).
-
The expansion of the large catalogue of Chinese medicinal materials is about to enter the market by China Resources and Jiang Zhongzhong
Time of Update: 2022-10-25
Second, set off a new product development boom China's current medicinal and food homologous products mostly enter the market in the form of traditional Chinese medicine pieces or medicinal diets, which can basically meet the daily needs of consumers, but due to simple preparation and low technical content, the added value of products is low and the core competitiveness is insufficient.
-
Hereditary angioedema (HAE) new drug! Takhzyro (rana lu monoclonal antib) received priority review by the US FDA: treatment of pediatric patients aged 2-12 years!
Time of Update: 2022-10-25
Food and Drug Administration Accepts Takeda's Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older Takhzyro is the first monoclonal antibody drug for the treatment of HAE, which specifically binds to and inhibits the activity of plasma kallikrein enzyme.
-
The performance of Kun Pharmaceutical Group has grown, and the upward pressure on raw materials has increased!
Time of Update: 2022-10-25
Baishu, Henan and other production areas began to produce new, it is expected that this year's new goods output is not large, the market source of small quantities continues to be good, merchants actively purchase and sell, the market has maintained stable operation in recent times, the price of Anhui biennial tablets is between 32-33 yuan, and the market is optimistic.
-
The end of 2022 is approaching, and pharmaceutical executives are leaving!
Time of Update: 2022-10-25
On October 10, Hengrui Pharmaceutical announced that the company's board of directors recently received a resignation report from Tao Weikang, deputy general manager of the company, and after resigning from the above position due to personal reasons, Tao Weikang will no longer hold any position in the company.
-
The first generic drug has become a place for pharmaceutical companies, and a large number of drugs will be the first imitation
Time of Update: 2022-10-25
In terms of generic drugs, in addition to Shuanghe Pharmaceutical, which reported production this time, Sichuan Guowei Pharmaceutical submitted a marketing application in November 2021, which is still under review and approval.
-
The NMPA approved the registration of 222 medical device product announcements
Time of Update: 2022-10-25
, Ltd The national weapon is 20223221181 The national weapon is 20223221181 41 Single-use endovascular imaging catheters Tianjin Hengyu Medical Technology Co.
, Ltd The national weapon is 20223401239 The national weapon is 20223401239 99 Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (Fluorescent PCR Method) Shenzhen Taylor Medical Co.
-
Biotech Survive Broken Tail! Stone Medicine, Zhongsheng, GSK, BMS, Pfizer throw olive branches! Is it time to dig the bottom?
Time of Update: 2022-10-25
01 Go in both directions, each take what you need Biotech joins hands with Big Pharma to survive the winter On April 1 this year, Nature Reviews Drug Discovery published a statistical article on the field of innovative drugs in China, and the content analysis pointed out that as of July 1, 2021, there were 2,251 drugs (including drugs and biological products) under development in all therapeutic areas in China, including 418 first-in-class, 473 fast-follower, and 923 me-too.
